论文部分内容阅读
BTLA是近年发现的CD28家族共抑制受体,主要表达于T、B细胞,在DC、单核及NK细胞上也有表达,其结构和功能与其它两种抑制性受体CTLA-4和PD-1相似。已证明BTLA的配体是HVEM,两者结合可负性调节T、B细胞的激活与增殖。最近研究发现BTLA与多种免疫性疾病(如自身免疫性疾病、移植排斥反应、肿瘤等)的发生、发展有关。随着对BTLA生物学功能研究的不断深入,必将阐明BTLA在免疫性疾病发生、发展中的作用及机理,为免疫性疾病治疗提供新思路。
BTLA is a CD28 family co-suppression receptor found in recent years. It is mainly expressed on T and B cells, and is also expressed on DCs, monocytes and NK cells. Its structure and function are similar to the other two inhibitory receptors CTLA-4 and PD- 1 is similar. It has been demonstrated that the ligand of BTLA is HVEM, and the combination of the two can negatively regulate the activation and proliferation of T and B cells. Recent studies found that BTLA and a variety of immune diseases (such as autoimmune diseases, transplant rejection, cancer, etc.) the occurrence and development. With the deepening of the research on the biological function of BTLA, it is bound to clarify the role and mechanism of BTLA in the occurrence and development of immune diseases, and provide new ideas for the treatment of immune diseases.